Home Medicine Multivariate approaches to improve the interpretation of laboratory data
Article Open Access

Multivariate approaches to improve the interpretation of laboratory data

  • Mario Plebani ORCID logo EMAIL logo
Published/Copyright: August 22, 2025

More than two decades ago, Callum Fraser provided evidence that the “normal” values of many measurands lie within a much narrower range than the population-based reference interval (RI) [1]. Furthermore, quantitative studies on within- and between-subject biological variation have shown that most laboratory measurands exhibit marked individuality. This individuality can be quantified using the index of individuality (II), first introduced by Harris in 1981 [2]. Despite this, individual test results are still commonly interpreted against broad population-based reference intervals. Such an approach neglects a crucial fact: many measurands are highly individualized and regulated around unique, stable values – so-called setpoints – which differ significantly between individuals. Recently, Foy et al., writing in Nature, presented compelling evidence underscoring the clinical importance of these personalized set points. By analyzing decades of blood-test data across nine key parameters, they demonstrated that incorporating personalized reference intervals into clinical diagnostics could advance precision medicine to a new level [3]. In an accompanying editorial, Steven J. R. Meex and Kristin Moberg Aakre highlighted that “personalized reference intervals offer an exciting path forward, potentially reshaping how preventive medicine is viewed” [4]. At the same time, they cautioned that “these models are rarely implemented in routine practice” owing to high model uncertainty and the difficulty of establishing whether observed changes truly reflect clinically relevant variation – factors that currently limit their widespread adoption. We have recently emphasized that a fundamental step in advancing value-based laboratory medicine (VBLM) is enhancing the interpretation of laboratory results through the adoption of objective criteria [5]. In fact, the interpretation of laboratory results is a comparative process that necessitates the availability of reliable additional information beyond the numerical data itself, including accurate terminology, harmonized measurement units, reference values such as reference intervals (RI) and decision limits (DL), and interpretative comments. These parameters, usually defined as “comparators” aim to make the data “actionable” [6]. In addition to the lack of harmonization in the adoption of the recommended measurement units, current references used for decision-making practice still rely on data derived from population studies. Recently, Coskun and Coll. developed an algorithm to estimate personalized reference intervals (pRI) based on analytes homeostatic set points (HSPs) and within-subject biological variations (CVI) [7], [8], thus providing new evidence and findings for replacing population-based reference data. In this issue of the Journal, Coskun and coll. move to another fundamental step in improving the interpretation of laboratory results. The authors, in fact, underline that current interpretation practices apply reference intervals and reference change values in a univariate manner – that is, each analyte in the panel is interpreted independently and no reference data are available to interpret the panel as a whole [9]. However, clinicians use test panels containing multiple analytes to enhance clinical significance and improve the accuracy of decision-making. As correctly highlighted by Coskun and coll. “metabolism is a network of biomolecules, each of which is related to others” [9]. Thus, a paradigm shift is necessary in interpreting patients’ laboratory data. Measurands should be evaluated collectively to capture the metabolic and functional state of the organism. This necessitates a multivariate approach, applying multivariate RIs (MRIs) to panels of related analytes. According to the Authors “multivariate approaches – such as MRI and multivariate reference change value (MRCV) – which are based on the correlations among measurands, offer a more comprehensive and metabolically oriented framework to interpret laboratory data. This enables a more realistic and clinically relevant assessment of patient results. The model also provides a pragmatic solution for the interpretation of omics data. In particular, proteomics and metabolomics have yielded valuable insights into alterations in protein profiles and biomolecules associated with disease [10]. Nevertheless, despite extensive research, the clinical translation of these multiple analytes has remained limited, highlighting a persistent gap between discovery and routine medical practice. As a clinically meaningful and pragmatic strategy, grouping biomarkers into relevant panels and interpreting them collectively – with the support of MRI for the entire panel – rather than individually, may accelerate their clinical implementation and enhance the accuracy of diagnosis and decision-making. Although the models described by the authors seem quite complex, the availability of advanced information technologies and further recently published information [11] should allow clinical laboratories to apply these concepts in clinical practice. The laboratory report, through the quality of the information it conveys, serves as the true calling card for both clinicians and patients, with personalized reference intervals providing the essential key to the correct interpretation of laboratory data. Enhancing the laboratory report, therefore, represents a fundamental opportunity to advance Value-Based Laboratory Medicine (VBLM).


Corresponding author: Mario Plebani, Department of Medicine-DIMED, University of Padova, Padova, Italy, E-mail:

  1. Research ethics: Not applicable.

  2. Informed consent: Not applicable.

  3. Author contributions: The author has accepted responsibility for the entire content of this manuscript and approved its submission.

  4. Use of Large Language Models, AI and Machine Learning Tools: None declared.

  5. Conflict of interest: The author states no conflict of interest.

  6. Research funding: None declared.

  7. Data availability: Not applicable.

References

1. Fraser, CG. Biological variation: from principles to practice. Washington DC: AACC Press; 2001.Search in Google Scholar

2. Harris, EK. Statistical aspects of reference values in clinical pathology. Prog Clin Pathol 1981;8:45–66.Search in Google Scholar

3. Foy, BH, Petherbridge, R, Roth, MT, Zhang, C, De Souza, DC, Mow, C, et al.. Haematological setpoints are a stable and patient-specific deep phenotype. Nature 2025;637:430–8. https://doi.org/10.1038/s41586-024-08264-5.Search in Google Scholar PubMed PubMed Central

4. Meex, SJR, Aakre, KM. Personalized ranges for blood-test results enable precision diagnostics. Nature 2025;637:279–80. https://doi.org/10.1038/d41586-024-03854-9.Search in Google Scholar PubMed

5. Plebani, M, Coskun, A. Promoting value-based laboratory medicine: moving towards an innovative model of clinical laboratory. Clin Chim Acta 2025;572:120269. https://doi.org/10.1016/j.cca.2025.120269.Search in Google Scholar PubMed

6. Plebani, M. Advancing value-based laboratory medicine. Clin Chem Lab Med 2024;63:249–57. https://doi.org/10.1515/cclm-2024-0823.Search in Google Scholar PubMed

7. Coşkun, A, Sandberg, S, Unsal, I, Cavusoglu, C, Serteser, M, Kilercik, M, et al.. Personalized reference intervals in laboratory medicine: a new model based on within-subject biological variation. Clin Chem 2021;67:374–84. https://doi.org/10.1093/clinchem/hvaa233.Search in Google Scholar PubMed

8. Coşkun, A, Sandberg, S, Unsal, I, Cavusoglu, C, Serteser, M, Kilercik, M, et al.. Personalized and population-based reference intervals for 48 common clinical chemistry and hematology measurands: a comparative study. Clin Chem 2023;69:1009–30. https://doi.org/10.1093/clinchem/hvad113.Search in Google Scholar PubMed

9. Coskun, A, Weninger, J, Canbay, A, Özçürümez, MK. From metabolic profiles to clinical interpretation: multivariate approaches to population-based and personalized reference intervals and reference change values. Clin Chem Lab Med 2025;63:2397–405. https://doi.org/10.1515/cclm-2025-0786.Search in Google Scholar PubMed

10. Coskun, A, Lippi, G. Personalized laboratory medicine in the digital health era: recent developments and future challenges. Clin Chem Lab Med 2023;62:402–9. https://doi.org/10.1515/cclm-2023-0808.Search in Google Scholar PubMed

11. Coskun, A, Plebani, M. Reference intervals in value-based laboratory medicine: a shift from single-point measurements to metabolic variation-based models. Clin Chem Lab Med 2025;63:2140–8. https://doi.org/10.1515/cclm-2025-0763.Search in Google Scholar PubMed

Published Online: 2025-08-22
Published in Print: 2025-11-25

© 2025 the author(s), published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Frontmatter
  2. Editorials
  3. Challenging the dogma: why reviewers should be allowed to use AI tools
  4. Multivariate approaches to improve the interpretation of laboratory data
  5. Review
  6. Interference of therapeutic monoclonal antibodies with electrophoresis and immunofixation of serum proteins: state of knowledge and systematic review
  7. Opinion Papers
  8. Urgent call to the European Commission to simplify and contextualize IVDR Article 5.5 for tailored and precision diagnostics
  9. The importance of laboratory medicine in the management of CKD-MBD: insights from the KDIGO 2023 controversies conference
  10. Supplementation of pyridoxal-5′-phosphate in aminotransferase reagents: a matter of patient safety
  11. HCV serology: an unfinished agenda
  12. From metabolic profiles to clinical interpretation: multivariate approaches to population-based and personalized reference intervals and reference change values
  13. Genetics and Molecular Diagnostics
  14. A multiplex allele specific PCR capillary electrophoresis (mASPCR-CE) assay for simultaneously analysis of SMN1/SMN2/NAIP copy number and SMN1 loss-of-function variants
  15. General Clinical Chemistry and Laboratory Medicine
  16. From assessment to action: experience from a quality improvement initiative integrating indicator evaluation and adverse event analysis in a clinical laboratory
  17. Evaluation of measurement uncertainty of 11 serum proteins measured by immunoturbidimetric methods according to ISO/TS 20914: a 1-year laboratory data analysis
  18. Assessing the harmonization of current total vitamin B12 measurement methods: relevance and implications
  19. The current status of serum insulin measurements and the need for standardization
  20. Method comparison of plasma and CSF GFAP immunoassays across multiple platforms
  21. Cerebrospinal fluid leptin in Alzheimer’s disease: relationship to plasma levels and to cerebrospinal amyloid
  22. Verification of the T50 Calciprotein Crystallization test: bias estimation and interferences
  23. An innovative immunoassay for accurate aldosterone quantification: overcoming low-level inaccuracy and renal dysfunction-associated interference
  24. Oral salt loading combined with postural stimulation tests for confirming and subtyping primary aldosteronism
  25. Evaluating the performance of a multiparametric IgA assay for celiac disease diagnosis
  26. Clinical significance of anti-mitochondrial antibodies and PBC-specific anti-nuclear antibodies in evaluating atypical primary biliary cholangitis with normal alkaline phosphatase levels
  27. Reference Values and Biological Variations
  28. Establishment of region-, age- and sex-specific reference intervals for aldosterone and renin with sandwich chemiluminescence immunoassays
  29. Validation of a plasma GFAP immunoassay and establishment of age-related reference values: bridging analytical performance and routine implementation
  30. Comparative analysis of population-based and personalized reference intervals for biochemical markers in peri-menopausal women: population from the PALM cohort study
  31. Hematology and Coagulation
  32. Evaluation of stability and potential interference on the α-thalassaemia early eluting peak and immunochromatographic strip test for α-thalassaemia --SEA carrier screening
  33. Cardiovascular Diseases
  34. Analytical and clinical evaluation of an automated high-sensitivity cardiac troponin I assay for whole blood
  35. Diabetes
  36. Method comparison of diabetes mellitus associated autoantibodies in serum specimens
  37. Letters to the Editor
  38. Permitting disclosed AI assistance in peer review: parity, confidentiality, and recognition
  39. Response to the editorial by Karl Lackner
  40. Hemolysis detection using the GEM 7000 at the point of care in a pediatric hospital setting: does it affect outcomes?
  41. Estimation of measurement uncertainty for free drug concentrations using ultrafiltration
  42. Cryoglobulin pre-analysis over the weekend
  43. Accelerating time from result to clinical action: impact of an automated critical results reporting system
  44. Recent decline in patient serum folate test levels using Roche Diagnostics Folate III assay
  45. Kidney stones consisting of 1-methyluric acid
  46. Congress Abstracts
  47. 7th EFLM Conference on Preanalytical Phase
  48. Association of Clinical Biochemists in Ireland Annual Conference
  49. Association of Clinical Biochemists in Ireland Annual Conference
  50. 17th Congress of the Portuguese Society of Clinical Chemistry, Genetics and Laboratory Medicine
Downloaded on 16.12.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2025-1071/html
Scroll to top button